Skip to main content
Feedback to SSRN
Feedback
(required)
Email
(required)
Submit
Changhong Zhao
Jiangsu Hengrui Pharmaceuticals Co., Ltd.
Learn more about SSRN Profiles
SCHOLARLY PAPERS
1
DOWNLOADS
57
TOTAL CITATIONS
0
Feedback
Scholarly Papers (1)
Sort by:
Paper Title, A-Z
Paper Title, Z-A
Author Name, A-Z
Author Name, Z-A
Date Posted, Ascending
Date Posted, Descending
Downloads, Ascending
Downloads, Descending
Citations, Ascending
Citations, Descending
Actions:
Email selected abstracts
View:
Selected
Original List
All Versions
Hide All Versions
All Abstracts
Hide All Abstracts
(Rank)
1.
Camrelizumab Plus Nab-Paclitaxel and Carboplatin as First-Line Treatment for Extensive-Stage Small-Cell Lung Cancer (ES-SCLC): A Phase II Trial
Number of pages: 19
Posted: 05 Feb 2024
Jia Yu
,
Anwen Xiong
,
Lei Wang
,
Xinlong Zheng
,
Tao Jiang
,
Qi Wang
,
Bin Chen
,
Menghang Yang
,
Wei Li
,
Jiajia Yuan
, Changhong Zhao,
Xiaohui Chen
,
Caicun Zhou
and
Shengxiang Ren
Tongji University - Department of Oncology, Tongji University - Department of Oncology, Tongji University - Department of Oncology, Fujian Medical University - Fujian Medical University Cancer Hospital, Tongji University - Department of Oncology, Tongji University - Shanghai Pulmonary Hospital, Tongji University - Department of Oncology, Tongji University - Department of Oncology, Tongji University - Department of Oncology, Jiangsu Hengrui Pharmaceuticals Co., Ltd., Jiangsu Hengrui Pharmaceuticals Co., Ltd., Fujian Medical University - Department of Thoracic Surgery, Tongji University - Department of Medical Oncology and Tongji University - Department of Medical Oncology
Downloads
57
(798,545)
View PDF
Download
Abstract:
Camrelizumab, Nab-paclitaxel, Immunotherapy, ES-SCLC
Feedback
